Differential loss of striatal projection neurons in Huntington disease.

Striatal plasticity and basal ganglia circuit function. Neuron (2008) 3.89

Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol (2009) 2.93

Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol (2004) 2.65

Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study. J Neurol Neurosurg Psychiatry (2005) 2.54

Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci U S A (2003) 2.35

The corticostriatal pathway in Huntington's disease. Prog Neurobiol (2006) 1.99

Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription. Proc Natl Acad Sci U S A (2004) 1.89

Transcriptional signatures in Huntington's disease. Prog Neurobiol (2007) 1.86

Basal Ganglia disorders associated with imbalances in the striatal striosome and matrix compartments. Front Neuroanat (2011) 1.85

Population-specific expression analysis (PSEA) reveals molecular changes in diseased brain. Nat Methods (2011) 1.70

Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. Neuroscience (2011) 1.62

Conditional routing of information to the cortex: a model of the basal ganglia's role in cognitive coordination. Psychol Rev (2010) 1.51

Protein aggregates in Huntington's disease. Exp Neurol (2011) 1.46

BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J Neurosci (2010) 1.44

Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J Neurosci (2009) 1.43

Knock-in mouse models of Huntington's disease. NeuroRx (2005) 1.40

Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. Dis Model Mech (2012) 1.31

Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc Natl Acad Sci U S A (1999) 1.30

Complex trait analysis of the mouse striatum: independent QTLs modulate volume and neuron number. BMC Neurosci (2001) 1.29

Therapeutic implications for striatal-enriched protein tyrosine phosphatase (STEP) in neuropsychiatric disorders. Pharmacol Rev (2011) 1.28

Differential electrophysiological changes in striatal output neurons in Huntington's disease. J Neurosci (2011) 1.27

Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat Neurosci (2014) 1.27

Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease molecular pathogenesis. J Neurosci (2010) 1.25

Huntington disease models and human neuropathology: similarities and differences. Acta Neuropathol (2007) 1.25

Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features. J Neurochem (2010) 1.25

Methamphetamine-induced cell death: selective vulnerability in neuronal subpopulations of the striatum in mice. Neuroscience (2006) 1.23

The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp Neurol (2007) 1.22

Striatal microcircuitry and movement disorders. Trends Neurosci (2012) 1.22

Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiol Dis (2008) 1.22

A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity. PLoS Genet (2012) 1.20

Self-paced timing detects and tracks change in prodromal Huntington disease. Neuropsychology (2010) 1.16

Huntingtin in health and disease. J Clin Invest (2003) 1.14

Developmental regulation and neuroprotective effects of striatal tonic GABAA currents. Neuroscience (2010) 1.14

Mouse models of Huntington's disease and methodological considerations for therapeutic trials. Biochim Biophys Acta (2009) 1.14

The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol (2010) 1.11

Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy. Proc Natl Acad Sci U S A (2009) 1.07

TrkB receptor controls striatal formation by regulating the number of newborn striatal neurons. Proc Natl Acad Sci U S A (2011) 1.07

Regionally selective atrophy of subcortical structures in prodromal HD as revealed by statistical shape analysis. Hum Brain Mapp (2012) 1.07

Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatr Dis Treat (2010) 1.06

Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry (1997) 1.05

Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease. Neurobiol Dis (2008) 1.05

Reassessing models of basal ganglia function and dysfunction. Annu Rev Neurosci (2014) 1.04

Multiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models. J Neurosci (2013) 1.04

Dopamine and glutamate in Huntington's disease: A balancing act. CNS Neurosci Ther (2010) 1.03

Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms. ASN Neuro (2010) 1.03

Neurodegenerative processes in Huntington's disease. Cell Death Dis (2011) 1.03

Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: interactions between neurons and astrocytes. Basal Ganglia (2012) 1.02

Brain networks in Huntington disease. J Clin Invest (2011) 1.02

Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation. Proc Natl Acad Sci U S A (2005) 1.01

Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction. Mol Neurodegener (2011) 1.01

Immunohistochemical visualization of afferent nerve terminals in human globus pallidus and its alteration in neostriatal neurodegenerative disorders. Acta Neuropathol (1989) 1.01

Antioxidants in Huntington's disease. Biochim Biophys Acta (2011) 1.00

Cortical and striatal neurone number in Huntington's disease. Acta Neuropathol (1994) 1.00

Firing rates of pallidal neurons are similar in Huntington's and Parkinson's disease patients. Exp Brain Res (2005) 1.00

Genetics and neuropathology of Huntington's disease. Int Rev Neurobiol (2011) 0.99

Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity. J Neurosci (2011) 0.98

Intrastriatal transplantation of cross-species fetal striatal cells reduces abnormal movements in a primate model of Huntington disease. Proc Natl Acad Sci U S A (1992) 0.97

Pallidal neuronal discharge in Huntington's disease: support for selective loss of striatal cells originating the indirect pathway. Exp Neurol (2008) 0.96

Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse. Hum Mol Genet (2008) 0.96

Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice. Neurobiol Dis (2013) 0.95

Activin A directs striatal projection neuron differentiation of human pluripotent stem cells. Development (2015) 0.95

New insight in expression, transport, and secretion of brain-derived neurotrophic factor: Implications in brain-related diseases. World J Biol Chem (2014) 0.93

Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats. Exp Neurol (2010) 0.93

Differential localization of the GluR1 and GluR2 subunits of the AMPA-type glutamate receptor among striatal neuron types in rats. J Chem Neuroanat (2007) 0.93

Changes in striatal procedural memory coding correlate with learning deficits in a mouse model of Huntington disease. Proc Natl Acad Sci U S A (2011) 0.93

Regulation of prefrontal excitatory neurotransmission by dopamine in the nucleus accumbens core. J Physiol (2012) 0.92

Motor tics evoked by striatal disinhibition in the rat. Front Syst Neurosci (2013) 0.92

The biological function of the Huntingtin protein and its relevance to Huntington's Disease pathology. Curr Trends Neurol (2011) 0.90

The Role of Striatal-Enriched Protein Tyrosine Phosphatase (STEP) in Cognition. Front Neuroanat (2011) 0.90

BDNF signaling and survival of striatal neurons. Front Cell Neurosci (2014) 0.90

Genome-wide association identifies genetic variants associated with lentiform nucleus volume in N = 1345 young and elderly subjects. Brain Imaging Behav (2013) 0.89

Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease. Mov Disord (2012) 0.89

The basal ganglia, the ideal machinery for the cost-benefit analysis of action plans. Front Neural Circuits (2013) 0.89

Cognitive training modifies disease symptoms in a mouse model of Huntington's disease. Exp Neurol (2016) 0.89

Striatal parvalbuminergic neurons are lost in Huntington's disease: implications for dystonia. Mov Disord (2013) 0.88

Antisense therapy in neurology. J Pers Med (2013) 0.87

Dopamine D2 receptor stimulation potentiates PolyQ-Huntingtin-induced mouse striatal neuron dysfunctions via Rho/ROCK-II activation. PLoS One (2009) 0.86

CalDAG-GEFI down-regulation in the striatum as a neuroprotective change in Huntington's disease. Hum Mol Genet (2010) 0.86

ER stress-induced eIF2-alpha phosphorylation underlies sensitivity of striatal neurons to pathogenic huntingtin. PLoS One (2014) 0.85

Transgenic animal models of neurodegeneration based on human genetic studies. J Neural Transm (Vienna) (2010) 0.85

Generation of striatal projection neurons extends into the neonatal period in the rat brain. J Physiol (2012) 0.85

Induced Pluripotent Stem Cells in Huntington's Disease Research: Progress and Opportunity. J Huntingtons Dis (2016) 0.85

Selective expression of mutant huntingtin during development recapitulates characteristic features of Huntington's disease. Proc Natl Acad Sci U S A (2016) 0.85

BDNF-TrkB signaling in striatopallidal neurons controls inhibition of locomotor behavior. Nat Commun (2013) 0.85

A large scale Huntingtin protein interaction network implicates Rho GTPase signaling pathways in Huntington disease. J Biol Chem (2014) 0.84

Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases. Int J Mol Sci (2014) 0.84

Huntington's disease: Neural dysfunction linked to inositol polyphosphate multikinase. Proc Natl Acad Sci U S A (2015) 0.84

Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease. Drug Des Devel Ther (2015) 0.83

Enhanced GABAergic Inputs Contribute to Functional Alterations of Cholinergic Interneurons in the R6/2 Mouse Model of Huntington's Disease. eNeuro (2015) 0.83

Huntington's disease: pathogenesis, diagnosis and treatment. J Psychiatry Neurosci (1994) 0.83

Purkinje cell dysfunction and loss in a knock-in mouse model of Huntington disease. Exp Neurol (2012) 0.83

Adenoviral astrocyte-specific expression of BDNF in the striata of mice transgenic for Huntington's disease delays the onset of the motor phenotype. Cell Mol Neurobiol (2011) 0.83

Endoplasmic reticulum stress and Parkinson's disease: the role of HRD1 in averting apoptosis in neurodegenerative disease. Oxid Med Cell Longev (2013) 0.83

Differentiation of pluripotent stem cells into striatal projection neurons: a pure MSN fate may not be sufficient. Front Cell Neurosci (2014) 0.83

The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice. Neurobiol Dis (2012) 0.83

Restricted transgene expression in the brain with cell-type specific neuronal promoters. Hum Gene Ther Methods (2012) 0.83

Benign hereditary chorea: dopaminergic brain imaging in patients with a novel intronic NKX2.1 gene mutation. J Neurol (2012) 0.83

Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines. J Cell Mol Med (2011) 0.83

Treatment of Huntington's disease. Neurotherapeutics (2014) 0.82

Huntington's Disease: From Mutant Huntingtin Protein to Neurotrophic Factor Therapy. Int J Biomed Sci (2011) 0.82

A polymorphic DNA marker genetically linked to Huntington's disease. Nature (1984) 16.71

Huntington's disease. Pathogenesis and management. N Engl J Med (1986) 2.77

Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature (1986) 2.29

Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science (1985) 2.23

HUNTINGTON'S CHOREA IN CHILDHOOD. Arch Neurol (1963) 2.01

Morphometric studies of the neuropathological changes in choreatic diseases. J Neurol Sci (1976) 1.92

Huntington's disease in Venezuela: neurologic features and functional decline. Neurology (1986) 1.39

Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue. Brain (1980) 1.29

Ramifications of the globus pallidus in the rat as indicated by patterns of immunohistochemistry. Neuroscience (1983) 1.23

Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res (1987) 1.11

Striatal inhomogeneities and basal ganglia function. Mov Disord (1986) 1.11

Saccades in Huntington's disease: initiation defects and distractibility. Neurology (1987) 1.10

Gamma-aminobutyric acid and benzodiazepine receptor changes induced by unilateral 6-hydroxydopamine lesions of the medial forebrain bundle. J Neurochem (1985) 1.04

Localization of immunoreactive enkephalins in GABA synthesizing neurons of the rat neostriatum. Brain Res (1984) 1.03

Light and electron microscopic localization of immunoreactive Leu-enkephalin in the monkey basal ganglia. J Neurosci (1982) 0.99

Distribution of enkephalin-related peptides in rat brain: immunohistochemical studies using antisera to met-enkephalin and met-enkephalin Arg6Phe7. Neuroscience (1983) 0.99

Striatal axons to the globus pallidus, entopeduncular nucleus and substantia nigra come mainly from separate cell populations in cat. Neuroscience (1986) 0.97

Regional distribution of methionine-enkephalin and substance P-like immunoreactivity in normal human brain and in Huntington's disease. Brain Res (1980) 0.95

Huntington's disease. A decade of progress. Neurol Clin (1984) 0.93

Immunocytochemical studies of substance P and Met-enkephalin in the basal ganglia and substantia nigra in Huntington's, Parkinson's and Alzheimer's diseases. J Neuropathol Exp Neurol (1985) 0.92

Modulation of striatal enkephalinergic neurons by antipsychotic drugs. Fed Proc (1985) 0.92

Identification of different subpopulations of neostriatal neurones projecting to globus pallidus or substantia nigra in the monkey: a retrograde fluorescence double-labelling study. Neurosci Lett (1984) 0.90

Human brain substance P: distribution in controls and Huntington's chorea. J Neurochem (1978) 0.90

The distribution of proenkephalin-derived peptides in the central nervous system of turtles. J Comp Neurol (1987) 0.90

Reduction in basal ganglia and substantia nigra substance P levels in Huntington's disease. Brain Res (1981) 0.89

Benzodiazepine and GABA receptors in early Huntington's disease. Neurology (1984) 0.89

Immunohistochemical and biochemical studies on Lys8-Asn9-neurotensin8-13 (LANT6)-related peptides in the basal ganglia of pigeons, turtles, and hamsters. J Comp Neurol (1987) 0.89

Immunocytochemical studies of substance P and leucine-enkephalin in Huntington's disease. Brain Res (1983) 0.85

Methionine-enkephalin and substance P in the basal ganglia of normals, Parkinson patients, Huntington patients, and schizophrenics. A qualitative immunohistochemical study. Acta Neuropathol (1985) 0.84

Experimental choreoathetosis produced by injection of a gamma-aminobutyric acid antagonist into the lentiform nucleus in the monkey. Neurosci Lett (1984) 0.84

Studies on neurotransmitter markers and striatal neuronal cell density in Huntington's disease and dentatorubropallidoluysian atrophy. J Neurol Sci (1985) 0.83

Differential effects of acute and chronic administration of haloperidol on substance P and enkephalins in diverse rat brain areas. Neuropsychobiology (1986) 0.81

The functional anatomy of basal ganglia disorders. Trends Neurosci (1989) 12.28

The molecular basis of lung morphogenesis. Mech Dev (2000) 4.87

Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet (2001) 3.84

Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet (2000) 3.07

The role of radiotracer imaging in Parkinson disease. Neurology (2005) 3.02

Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature (1999) 2.97

Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology (2000) 2.49

Homozygotes for Huntington's disease. Nature (1987) 2.40

Strychnine binding associated with glycine receptors of the central nervous system. Proc Natl Acad Sci U S A (1973) 2.37

Anatomical and affinity state comparisons between dopamine D1 and D2 receptors in the rat central nervous system. Neuroscience (1989) 2.29

Gamma-aminobutyric acid binding to receptor sites in the rat central nervous system. Proc Natl Acad Sci U S A (1974) 2.29

Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci U S A (1998) 2.14

Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell (1997) 2.13

Cell migrations to the isocortex in the rat. Anat Rec (1968) 2.12

History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology (2009) 2.01

Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference Participants. Ann Neurol (1997) 1.94

Etiology of progressive multifocal leukoencephalopathy. Identification of papovavirus. N Engl J Med (1973) 1.90

Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. N Engl J Med (1990) 1.89

Studies of the antigenic relationships of the new human papovaviruses by electron microscopy agglutination. Infect Immun (1973) 1.84

Huntingtin localization in brains of normal and Huntington's disease patients. Ann Neurol (1997) 1.82

Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Natl Acad Sci U S A (2001) 1.79

Clinical assessment of 31 patients with Wilson's disease. Correlations with structural changes on magnetic resonance imaging. Arch Neurol (1987) 1.78

Glutamic acid: selective depletion by viral induced granule cell loss in hamster cerebellum. Brain Res (1974) 1.77

Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord (1990) 1.76

Synaptic biochemistry of amino acids. Fed Proc (1973) 1.74

Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. J Comp Neurol (1994) 1.73

Huntington disease: no evidence for locus heterogeneity. Genomics (1989) 1.70

Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nat Genet (1993) 1.67

Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. J Neurosci (1994) 1.67

Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol (2001) 1.67

Recruitment behavior and program directors: how ethical are their perspectives about the match process? Fam Med (2000) 1.64

The functional anatomy of disorders of the basal ganglia. Trends Neurosci (1995) 1.62

Treatment for patients with cerebral metastases. Arch Neurol (1978) 1.60

Retracted Heparin-binding growth factor 1 induces the formation of organoid neovascular structures in vivo. Proc Natl Acad Sci U S A (1989) 1.59

Evaluation of traumatic atlantooccipital dislocations. AJNR Am J Neuroradiol (1987) 1.57

Surfactant (beractant) therapy for infants with congenital diaphragmatic hernia on ECMO: evidence of persistent surfactant deficiency. J Pediatr Surg (1994) 1.54

PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol (1986) 1.53

Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch Neurol (1991) 1.53

The urology residency matching program in practice. J Urol (2000) 1.46

Effect of extracorporeal membrane oxygenation on survival of infants with congenital diaphragmatic hernia. J Pediatr (1990) 1.46

Autoradiographic characterization of N-methyl-D-aspartate-, quisqualate- and kainate-sensitive glutamate binding sites. J Pharmacol Exp Ther (1985) 1.44

Papovavirus of JC type in progressive multifocal leukoencephalopathy. Rapid identification and subsequent isolation. Arch Neurol (1973) 1.43

Patterns of injury in children. J Pediatr Surg (1990) 1.42

Interaction of benzodiazepines with central nervous glycine receptors: possible mechanism of action. Proc Natl Acad Sci U S A (1974) 1.41

Huntington's disease in Venezuela: neurologic features and functional decline. Neurology (1986) 1.39

Acute dyskinesias in young asthmatics treated with theophylline. Pediatr Neurol (1991) 1.39

NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J Neurosci (1995) 1.37

Requirement for fibroblast growth factor 10 or fibroblast growth factor receptor 2-IIIb signaling for cecal development in mouse. Dev Biol (2004) 1.36

The ciliary neurotrophic factor and its receptor, CNTFR alpha. Pharm Acta Helv (2000) 1.35

Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol (1996) 1.35

At-risk persons' attitudes toward presymptomatic and prenatal testing of Huntington disease in Michigan. Am J Med Genet (1987) 1.34

Virions from progressive multifocal leukoencephalopathy: rapid serological identification by electron microscopy. Science (1972) 1.33

The RNA-binding protein HuD is required for GAP-43 mRNA stability, GAP-43 gene expression, and PKC-dependent neurite outgrowth in PC12 cells. Mol Biol Cell (2000) 1.32

Distribution and kinetics of GABAB binding sites in rat central nervous system: a quantitative autoradiographic study. Neuroscience (1990) 1.32

Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology (1996) 1.32

Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann Neurol (1992) 1.31

Primary culture of capillary endothelium from rat brain. In Vitro (1981) 1.30

Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional anatomy of chorea and rigidity-akinesia. Ann Neurol (1990) 1.29

Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study. J Chem Neuroanat (2004) 1.27

Neuronal and oligodendroglial infection by the WW strain of Theiler's virus. Lab Invest (1979) 1.25

Excitatory amino acids and Alzheimer's disease. Neurobiol Aging (1989) 1.24

Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease. Ann Neurol (2000) 1.23

Outcome measures in spinal cord injury: recent assessments and recommendations for future directions. Spinal Cord (2009) 1.23

Gastroschisis in the United States 1988-2003: analysis and risk categorization of 4344 patients. J Perinatol (2006) 1.23

NMDA receptor losses in putamen from patients with Huntington's disease. Science (1988) 1.21

Hypoxanthine-guanine phosphoribosyltransferase deficiency. The molecular basis of the clinical syndromes. N Engl J Med (1983) 1.21

Expression of NMDAR2D glutamate receptor subunit mRNA in neurochemically identified interneurons in the rat neostriatum, neocortex and hippocampus. Brain Res Mol Brain Res (1996) 1.21

Expression of normal and mutant huntingtin in the developing brain. J Neurosci (1996) 1.21

Criteria for extracorporeal membrane oxygenation in a population of infants with persistent pulmonary hypertension of the newborn. J Pediatr Surg (1986) 1.20

Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J Neural Transm (Vienna) (2005) 1.20

Speculations on the functional anatomy of basal ganglia disorders. Annu Rev Neurosci (1983) 1.18

Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism. Neurogenetics (2001) 1.18